Rapid Identification of SARS-CoV-2 Omicron BA.5 Spike Mutation F486V in Clinical Specimens Using a High-Resolution Melting-Based Assay

Akira Aoki 1, Hirokazu Adachi 2, Yoko Mori 1, Miyabi Ito 2, Katsuhiko Sato 2, Masayoshi Kinoshita 2, Masahiro Kuriki 2-3, Kenji Okuda 2-4, Toru Sakakibara 2-5, Yoshinori Okamoto 1 and Hideto Jinno 1,*

1 Faculty of Pharmacy, Meijo University, 150 Yagotoyama, Tempaku-ku, Nagoya 468-8503, Japan
2 Aichi Prefectural Institute of Public Health, 7-6 Nagare, Tsuji-machi, Kita-ku, Nagoya 462-8576, Japan
3 Kiyosu Health Center, 129 Haruhi, Sakakibara, Kiyosu 452-0961, Japan
4 Handa Health Center, 1-45-4 Deguchi-cho, Handa 475-0903, Japan
5 Nishio Health Center, 12 Shimoda, Yorizumi-cho, Nishio 445-0073, Japan
* Correspondence: jinno@meijo-u.ac.jp

Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant BA.5 emerged as of February 2022 and replaced the earlier Omicron subvariants BA.1 and BA.2. COVID-19 genomic surveillance should be continued as new variants seem to subsequently appear, including post-BA.5 subvariants. A rapid assay is needed to differentiate between the currently dominant BA.5 variant and other variants. This study successfully developed a high-resolution melting (HRM)-based assay for BA.4/5-characteristic spike mutation F486V detection and demonstrated that our assay could discriminate between BA.1, BA.2, and BA.5 subvariants in clinical specimens. The mutational spectra at two regions (G446/L452 and F486) for the variant-selective HRM analysis was the focus of our assay. The mutational spectra used as the basis to identify each Omicron subvariant were as follows: BA.1 (G446S/L452/F486), BA.2 (G446/L452/F486), and BA.4/5 (G446/L452R/F486V). Upon mutation-coding RNA fragment analysis, the wild-type fragments melting curves were distinct from those of the mutant fragments. Based on the analysis of 120 clinical samples (40 each of subvariants BA.1, BA.2, and BA.5), this method’s sensitivity and specificity were determined to be more than 95% and 100%, respectively. These results clearly demonstrate that this HRM-based assay is a simple screening method for monitoring Omicron subvariant evolution.

Keywords: severe acute respiratory syndrome coronavirus 2; high-resolution melting; Omicron subvariant; BA.5; F486V mutation

1. Introduction

The coronavirus disease 2019 (COVID-19) outbreak was caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that emerged in China in late 2019 [1–3]. The number of global COVID-19 cases surpassed 600 million according to the World Health Organization (WHO) data (Weekly epidemiological update on COVID-19, 7 September 2022), including over 6.4 million deaths. A number of SARS-CoV-2 variants emerged worldwide, some of which could potentially increase public health risk. The WHO has classified these as variants of concern (VOCs) and variants of interest (VOIs) since 2020. The COVID-19 genomic surveillance, tracking VOCs and VOIs, is essential in protecting against the spread of high-risk variants and monitoring new variants.

The novel VOC, the Omicron variant, emerged from South Africa in November 2021 [4–6]. The original Omicron variant BA.1 quickly spread to many countries and exceeded the other variants, including the Delta variant. The BA.2 subvariant of Omicron, which was more transmissible than BA.1 [7], rapidly increased since early 2022. The new Omicron subvariants BA.4 and BA.5 were first detected in South Africa in January and February...
2022, respectively. The two subvariants subsequently became mainstream in the country. Although BA.4 did not spread further around the world, BA.5 quickly spread across the world after a few months from BA.2 becoming the dominant variant. Furthermore, close monitoring of the Omicron variants’ evolution should continue since additional Omicron subvariants seem to emerge subsequently [8].

Next-generation sequencing (NGS) is the gold standard for determining the whole viral genome. NGS data leads to assigning a lineage or clade to each SARS-CoV-2 strain. A screening assay, which identifies a SARS-CoV-2 point mutation, can contribute to the rapid identification of the individual variants within a day as NGS analysis requires a few days to acquire the data. A few previous studies have shown that screening assays can differentiate the Omicron subvariants BA.1 and BA.2 based on their characteristic mutations [9–12]. The BA.5 subvariant has two characteristic spike mutations, L452R and F486V (BA.4 sequence identical to BA.5 sequence in spike protein) [13,14]. Wilhelm et al. [15] reported that Omicron subvariants BA.4 and BA.5 in wastewater could be detected by commercially available kits for L452R and E484A/F486V. However, there are no or limited studies that demonstrate Omicron subvariant BA.5 identification in clinical specimens by a screening assay.

High-resolution melting (HRM) analysis is a post-PCR genotyping technique based on an amplicons’ melting behavior. HRM-based assay is a less-costly and quick-build method as the assay does not need a specific probe. Our HRM-based assay was previously demonstrated to discriminate between the Omicron BA.1 and BA.2 subvariants targeting three mutations in the spike receptor-binding domain (RBD), R408, G446/L452, and T477/T478 [16]. In this study, we aimed to (i) develop an HRM-based assay to detect the F486V mutation and (ii) validate the HRM-based assay for L452/G446 and F486 sites in 120 clinical samples (40 each of the BA.1, BA.2, and BA.5 subvariants). This HRM-based assay would contribute to rapid discernment between BA.1 (G446S, L452, and F486), BA.2 (G446, L452, and F486), and BA.4/5 (G446, L452R, and F486V) (Table 1).

### Table 1. Receptor-binding domain (RBD) amino acid substitutions in Omicron BA.1, BA.2, BA.4, and BA.5 subvariants.

| Pangolin | RBD Amino Acid Substitutions |
|----------|-----------------------------|
| BA.1     | G339D, S371L, S373P, S375F, K417N, N440K, **G446S**, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H |
| BA.2     | G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H |
| BA.4/5   | G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, **L452R**, **F486V**, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H |

Substitutions detected by this high-resolution melting assay are marked in bold.

---

### 2. Materials and Methods

#### 2.1. Ethics Statement

The Meijo University Research Ethics Committee (Approval number: 2020-17-2) and Aichi Prefectural Institute of Public Health (Approval number: 20E-4) approved this project, and was carried out according to the Infectious Diseases Control Law of Japan.

#### 2.2. Preparation of Standard RNA Fragments: In Vitro T7 Transcription

The SARS-CoV-2 sequence was obtained from the NCBI (GenBank ID: MN908947), the GISAID database (www.gisaid.org/; accessed on 9 August 2022), and the Pango nomenclature system (https://cov-lineages.org/lineages.html; accessed on 9 August 2022). Eurofins Genomics K.K provided the three RBD DNA fragments (wild-type, F486V mutant, BA.4/5 variant mutant; 600–1000 bp in length) with a 5’ T7 upstream promoter sequence. (Tokyo, Japan). In vitro T7 transcription was performed as previously described [16,17]. The synthesized single-stranded RNA fragments were used as reverse transcriptase (RT)-PCR amplification templates.
2.3. RT-PCR Amplification: First PCR

A one-step RT-PCR kit (One Step PrimeScript III RT-qPCR Mix, with UNG; TaKaRa Bio Inc., Kusatsu, Japan) was used to perform RT-PCR in a single closed tube in accordance with the manufacturer’s instructions. The primer pairs used for RT-PCR amplification are listed in Table 2. Each DNA fragment was observed as a single, correctly sized band (290 bp). RT-PCR amplification was performed as previously described [16,17]. The reaction mixture was diluted 10,000-fold with water and used as a template for the second PCR and HRM analyses after amplification.

Table 2. Primers sequences in reverse transcriptase (RT)-PCR amplification and high-resolution melting (HRM) analysis.

| Primer            | RT-PCR amplification | HRM analysis |
|-------------------|----------------------|--------------|
| Fwd primer        | 5′-TTACAGGCTGCCTTATAG-3′ | 5′-GGCTGCGTTTACCTGGAATTCTAACAATCTT-3′ |
| Rev primer        | 5′-ACAAACAGTTGCTGGCATC-3′ | 5′-TCGAAGTTCGTTGATTTAATGCTCC-3′ |
| G446-L452 Fwd primer | 5′-GGCTGCGTTTACCTGGAATTCTAACAATCTT-3′ | 5′-ACACCTTGAATGTTGATTTAAGG-3′ |
| G446-L452 Rev primer | 5′-ACAAACAGTTGCTGGCATC-3′ | 5′-AGTGGGATGAAACCATATGATTG-3′ |
| F486 Fwd primer   | 5′-TTACAGGCTGCCTTATAG-3′ | 5′-GGCTGCGTTTACCTGGAATTCTAACAATCTT-3′ |
| F486 Rev primer   | 5′-ACAAACAGTTGCTGGCATC-3′ | 5′-TCGAAGTTCGTTGATTTAATGCTCC-3′ |

Fwd: forward; Rev: reverse.

2.4. HRM Analysis: Second PCR

An HRM reagent (MeltDoctor HRM Master Mix; Thermo Fisher Scientific, Waltham, MA, USA) was used to perform HRM according to the manufacturer’s instructions. The primer pairs for HRM analysis are listed in Table 2. Each DNA fragment was observed as a single, correctly sized band (G466-L452, 104 bp; F486, 69 bp). The G446-L452 forward primer design was based on the N440 coding sequence, the F486 forward primer design was based on the T478 and E484 coding sequences, and the F486 reverse primer design was based on the Q493 coding sequence to avoid the potential influences of the N440, T478, E484, and Q493 mutations as shown in Figure 1. A real-time PCR system (LightCycler 96 System; Roche Diagnostics, Basel, Switzerland) was used to perform all reactions in duplicate. PCR amplification and HRM curves were performed as previously described [16,17].

Figure 1. Primer annealing site schematic map for high-resolution melting analyses.

2.5. Clinical Samples

From December 2021 to August 2022, 120 nasopharyngeal swabs or saliva samples were collected from suspected COVID-19 and those detected with COVID-19 by the Aichi Prefectural Institute of Public Health. The Ct values in the clinical quantitative PCR test for
these samples ranged from 14–35. RNA purification and whole-genome sequencing were performed as previously described [16].

3. Results

3.1. Development of HRM Analysis for F486V Mutation Detection

First, the HRM-based assay for detecting F486V was developed, a characteristic mutation of BA.4/5. There are several SARS-CoV-2 variants possessing mutations near the F486 site, such as T478K, E484K, E484A, and Q493R. The risk of a false positive or false negative will likely increase in these variants using this assay. The primer sets were thus designed to avoid these mutations (Figure 1). The normalized melting curves and peaks for F486, F486V, and BA.4/5 RBD plots are shown in Figure 2. The F486V RBD plot was different from the F486 RBD plot. Additionally, the BA.4/5 RBD plot was in agreement with the F486V plot. These results suggested that this HRM-based assay can discriminate between the Omicron subvariant BA.4/5 (as the F486V variant) and other subvariants, including BA.1 and BA.2 (as the F486 wild-type).

Figure 2. Positive control RNAs normalized melting curves and melting peaks for the F486 site. Normalized melting curve plots (A) and melting peak plots (B) for the F486 site were acquired using F486 receptor-binding domain standard fragments (RBD; solid black line), F486V RBD (dashed black line), and BA.4/5 RBD (solid red line).

3.2. Validation of HRM Analysis for the G446/L452 and F486 Sites in Clinical Samples

Second, HRM-based assay was validated for G446/L452 and F486 sites in clinical samples infected with BA.1, BA.2, or BA.5. A total of 120 clinical samples (n = 40, BA.1; n = 40, BA.2; n = 40, BA.5) were randomly selected after whole-genome sequencing by NGS (Table 3). RBD sequences in all samples were identical to the reference sequence (BA.1, G446S/L452/F486; BA.2, G446/L452/F486; and BA.5, G446/L452R/F486V) confirmed by NGS data. HRM analysis together with positive control RNAs was used to analyze clinical samples. The Gene Scanning Software automatically classified samples into wild-type or mutant strains based on HRM curves after HRM analysis. The melting peak plots of representative samples at two RBD regions are shown in Figure 3. At the G446/L452 site, all BA.1 and BA.2 samples were correctly classified as G446S mutant and wild-type, respectively. The two BA.5 sample plots disagreed with the L452R RBD plot. All samples were correctly classified as each variant at the F486 site. Therefore, the sensitivity and specificity of the current HRM-based assay were calculated based on these results. The sensitivity and specificity of the assay for the two regions were more than 95% and 100%, respectively (Table 4).
Table 3. Pangolin of 120 clinical samples by whole-genome sequencing.

| Pangolin | No. of Samples | Ct Mean Value (Range) | Pangolin | No. of Samples | Ct Mean Value (Range) | Pangolin | No. of Samples | Ct Mean Value (Range) |
|----------|----------------|-----------------------|----------|----------------|-----------------------|----------|----------------|-----------------------|
| BA.1     | 11             | 25.2 (22.2–29.9)      | BA.2     | 10             | 23.0 (18.0–27.45)     | BA.5     | 3              | 23.2 (16.9–27.9)      |
| BA.1.1   | 5              | 24.2 (23.0–26.8)      | BA.2.3   | 14             | 25.7 (20.1–34.9)      | BA.5.1   | 2              | 22.2 (22.1–22.3)      |
| BA.1.1.2 | 8              | 24.6 (20.0–29.9)      | BA.2.3.1 | 7              | 23.9 (18.8–28.4)      | BA.5.2   | 12             | 25.0 (19.2–29.1)      |
| B.1.1.529| 16             | 27.4 (21.1–32.6)      | BA.2.3.13| 1              | 20.8                  | BA.5.2.1 | 1              | 23.8 (14.3–29.1)      |
| BA.2.10  | 4              | 24.7 (22.9–28.7)      | BA.2.3.13| 7              | 23.6                  | BE.1.1   | 2              | 21.3 (17.9–24.8)      |
| BA.2.10.2| 1              | 24.7                  | BA.2.24  | 2              | 21.4 (18.4–24.5)      | BF.5     | 6              | 24.1 (22.3–24.9)      |
| BA.2.24  | 2              | 21.4                  | BA.5.3.1 | 1              | 22.1                  |          |                |                       |
| BA.2.29  | 1              | 28.8                  |          |                |                       |          |                |                       |

Figure 3. Melting peaks of clinical samples for two receptor-binding domain regions. Melting peak plots for the G446/L452 (A) and F486 (B) sites were acquired using clinical samples with three BA.1 samples (blue line), three BA.2 samples (green line), and three BA.5 samples (red line). Solid lines indicate true positive and true negative samples. Dashed lines indicate false positive samples.

Table 4. High-resolution melting assay sensitivity and specificity compared with next-generation sequencing.

|                               | G446S Detection | L452R Detection | F486V Detection |
|-------------------------------|-----------------|-----------------|-----------------|
| Sensitivity \(^a\)            | 100% (40/40)    | 95.0% (38/40)   | 100% (40/40)    |
| Specificity \(^b\)            | 100% (80/80)    | 100% (80/80)    | 100% (80/80)    |

\(^a\) Sensitivity: True positive number/(True positive number + False Positive number) \times 100.
\(^b\) Specificity: False negative number/(False negative number + True negative number) \times 100.

4. Discussion

This is the first study conducted on developing a screening assay that can distinguish between the Omicron subvariant BA.5 and other subvariants in clinical samples. The assay costs less than USD 5 per sample, and the results can be obtained within 4 h. This HRM-based assay can be a powerful tool as a high-throughput screening test to identify the SARS-CoV-2 variants in many clinical samples.

The Omicron BA.5 subvariant seems to lead to lower mortality and hospitalization rates than earlier variants; however, the COVID-19 pandemic will not end this year [8]. A new high-risk variant will likely happen subsequently as the Omicron BA.5 subvariant is not considered the final SARS-CoV-2 variant [8]. Therefore, COVID-19 genomic surveillance should continue monitoring the next strain’s emergence. The BA.2.75 variant called Centaurus (non-WHO labeling) is one of the Omicron subvariants first detected in
India [18–21]. BA.2.75’s potential infectivity and immune evasion are unclear, indicating that the variant should be closely monitored. The assay for N460S mutation detection was still developed as our HRM-based assay can be constructed quickly, which is a BA.2.75 subvariant characteristic mutation. We will continue developing HRM-based assays to detect new variants with potentially high public health risks.

This study needs to be interpreted in the context of its limitations. First, this assay cannot differentiate between BA.4 and BA.5 subvariants since both variants possess identical spike protein sequences (Table 1). The assay will be developed to identify the BA.4 specific mutations as necessary, such as OFR1a-DEL141/143, ORF7b-D61L, and N-P151S [22]. Second, this assay was validated using a limited sample number. Our HRM-based assay should analyze a larger sample size. Third, the current assay’s detection limit should be determined using low-copy virus samples with Ct values of more than 35.

5. Conclusions

We developed an HRM-based assay that detects the SARS-CoV-2 spike mutation F486V, known as the Omicron subvariants BA.4/5-characteristic mutation. Based on the analysis of clinical samples with BA.1, BA.2, and BA.5, our assay showed enough sensitivity and specificity to distinguish among the three subvariants. Further studies are needed to validate this HRM-based assay using diverse samples with Ct values of more than 35. However, the current HRM-based assay can construct a cost-effective screening test without any specific probe.

Author Contributions: All the authors participated in the interpretation of the results. A.A. designed and conducted the HRM analyses and wrote the original manuscript draft. H.A. and M.I. conducted RNA purification, NGS analysis, and edited the manuscript. Y.M. performed sequence analyses. Y.O. planned the study and edited the manuscript. K.S., M.K. (Masayoshi Kinoshita), M.K. (Masahiro Kuriki), K.O., T.S. and H.J. planned the study and supervised the project. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported in part by the DAIKO FOUNDATION and Meijo University Research Project for Countermeasures Against COVID-19.

Institutional Review Board Statement: The Research Ethics Committee of Meijo University (approval No. 2020-17-4) and the Aichi Prefectural Institute of Public Health (approval No. 20E-4) approved this project.

Informed Consent Statement: Patient consent was waived because all clinical samples were obtained through the administrative actions process for COVID-19 diagnosis according to the Infectious Diseases Control Law in Japan.

Data Availability Statement: Data are unsuitable for public deposition due to ethical restrictions and the Infectious Diseases Control Law in Japan. The data presented in this study are available on request from the corresponding author. The data are not publicly available due to privacy restrictions.

Acknowledgments: The authors would like to thank the staff of the Laboratory of Virology, Department of Microbiology and Medical Zoology, Aichi Prefectural Institute of Public Health, who performed COVID-19 PCR testing, RNA purification from clinical samples, and NGS analysis.

Conflicts of Interest: The authors declare no competing interest.

References
1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 2020, 5, 536–544. [CrossRef] [PubMed]
2. Wu, F.; Zhao, S.; Yu, B.; Chen, Y.M.; Wang, W.; Song, Z.G.; Hu, Y.; Tao, Z.W.; Tian, J.H.; Pei, Y.Y.; et al. Author Correction: A new coronavirus associated with human respiratory disease in China. Nature 2020, 580, E7. [CrossRef] [PubMed]
3. Zhou, P.; Yang, X.L.; Wang, X.G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.R.; Zhu, Y.; Li, B.; Huang, C.L.; et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020, 579, 270–273. [CrossRef] [PubMed]
4. Karim, S.S.A.; Karim, Q.A. Omicron SARS-CoV-2 variant: A new chapter in the COVID-19 pandemic. Lancet 2021, 398, 2126–2128. [CrossRef]
5. Petersen, E.; Ntoumi, F.; Hui, D.S.; Abubakar, A.; Kramer, L.D.; Obiero, C.; Tambyah, P.A.; Blumberg, L.; Yapi, R.; Al-Abri, S.; et al. Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529)—Highlights Africa’s research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts. *Int. J. Infect. Dis.* 2022, 114, 268–272. [CrossRef]

6. Viana, R.; Moyo, S.; Amoako, D.G.; Tegally, H.; Scheepers, C.; Althaus, C.L.; Anyaneji, U.J.; Bester, P.A.; Boni, M.F.; Chand, M.; et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. *Nature* 2022, 603, 679–686. [CrossRef]

7. Yamasoba, D.; Kimura, I.; Nasser, H.; Morioka, Y.; Nao, N.; Ito, J.; Uriu, K.; Tsuda, M.; Zahradnik, J.; Shirakawa, K.; et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike. *Cell* 2022, 185, 2103–2115.e19. [CrossRef]

8. Callaway, E. What Omicron’s BA.4 and BA.5 variants mean for the pandemic. *Nature* 2022, 606, 848–849. [CrossRef]

9. Ayadi, W.; Taktak, A.; Gargouri, S.; Smaoui, F.; Chtourou, A.; Skouri-Gargouri, H.; Derbel, R.; Sassi, A.H.; Gargouri, A.; Hammami, A.; et al. Development of a simple genotyping method based on indel mutations to rapidly screen SARS-CoV-2 circulating variants: Delta, Omicron BA.1 and BA.2. *J. Virol. Methods* 2022, 307, 114570. [CrossRef]

10. Hirotsu, Y.; Maejima, M.; Shibusawa, M.; Natori, Y.; Nagakubo, Y.; Hosaka, K.; Sueki, H.; Mochizuki, H.; Tsutsui, T.; Kakizaki, Y.; et al. Classification of Omicron BA.1, BA.1.1, and BA.2 sublineages by TaqMan assay consistent with whole genome analysis data. *Int. J. Infect. Dis.* 2022, 122, 486–491. [CrossRef]

11. Wilhelm, A.; Agrawal, S.; Schoth, J.; Meinert-Berning, C.; Bastian, D.; Orschler, L.; Ciesek, S.; Teichgräber, B.; Lackner, S.; et al. Early detection of SARS-CoV-2 Omicron variants BA.1 and BA.2 in German wastewater. *Viruses* 2022, 14, 1876. [CrossRef]

12. Aoki, A.; Adachi, H.; Mori, Y.; Ito, M.; Sato, K.; Okuda, K.; Sakakibara, T.; Okamoto, Y.; Jinno, H. Discrimination of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 using a high-resolution melting-based assay: A pilot study. *Microbiol. Spectr.* 2022, 10, e01367-01322. [CrossRef] [PubMed]

13. Zappa, M.; Angeli, F. Knowing the new Omicron BA.2.75 variant (‘Centaurus’): A simulation study. *Eur. J. Intern. Med.* 2022, 105, 107–108. [CrossRef]

14. Sheward, D.J.; Kim, C.; Fischbach, J.; Muschiol, S.; Ehling, R.A.; Bjorkstrom, N.K.; Hestedam, G.B.K.; Reddy, S.T.; Albert, J.; Peacock, T.P.; et al. Evasion of neutralising antibodies by omicron sublineage BA.2.75. *Lancet Infect. Dis.* 2022, 22, 1421–1422. [CrossRef]

15. Desingu, P.A.; Nagarajan, K. The emergence of Omicron lineages BA.4 and BA.5, and the global spreading trend. *Hum. Hered.* 2022, 94, 5077–5079. [CrossRef] [PubMed]